公开(公告)号：US06635745B2

公开(公告)日：2003-10-21

申请号：US09757212

申请日：2001-01-09

申请人： Richard Sedrani ,  Valérie Quesniaux Ryffel

发明人： Richard Sedrani ,  Valérie Quesniaux Ryffel

IPC分类号： C07K110

CPC分类号： C07K16/1292

摘要： Monoclonal antibodies to rapamycin and to 40-O-alkylated derivatives of rapamycin are provided, together with novel haptens, immunogenic conjugates, and processes for making them and assay kits for using them.

公开(公告)号：US08846880B2

公开(公告)日：2014-09-30

申请号：US12994059

申请日：2009-05-20

申请人： Valérie Quesniaux Ryffel ,  Olivier Martin ,  Sophie Front

发明人： Valérie Quesniaux Ryffel ,  Olivier Martin ,  Sophie Front

IPC分类号： C07H15/00 ,  C07H21/00 ,  C07H15/207

CPC分类号： C07H15/207

摘要： The present invention relates to novel synthetic analogs of phosphatidyl-myo-inositol mannosides (hereinafter referred to as PIMs) of general formula (I): or a pharmaceutically acceptable salt thereof, to the method for preparing same and to the use thereof in the prevention or treatment of a disease associated with the overexpression of cytokines or of chemokines, in particular of TNF and/or of IL-12. The invention also relates to a pharmaceutical composition comprising at least one synthetic derivative of PIM.

摘要翻译： 本发明涉及通式（I）所示的磷脂酰肌醇甘露糖苷（以下称为PIM）的新型合成类似物或其药学上可接受的盐及其制备方法及其在预防中的应用 或治疗与细胞因子或趋化因子特别是TNF和/或IL-12的过度表达相关的疾病。 本发明还涉及包含PIM的至少一种合成衍生物的药物组合物。

公开(公告)号：US20100048492A1

公开(公告)日：2010-02-25

申请号：US12515450

申请日：2007-11-20

申请人： Valérie Quesniaux Ryffel ,  Germain Puzo ,  Jérôme Nigou ,  Martine Gilleron

发明人： Valérie Quesniaux Ryffel ,  Germain Puzo ,  Jérôme Nigou ,  Martine Gilleron

IPC分类号： A61K31/7028 ,  C07H11/04 ,  A61P29/00

CPC分类号： A61K31/7028

摘要： The present invention relates to a pharmaceutical composition comprising at least one compound of formula (I): or one of its pharmaceutically acceptable salts in which R1, R2 and R3 are independently a hydrogen or an R7—CO— group where R7 is an alkyl, alkene or alkyne group, linear, branched or cyclic, comprising 2 to 24 carbon atoms; R4 is a hydrogen atom or a mannosyl group substituted in position 6 by an R6 residue chosen from the group comprising a hydrogen atom and an R7—CO— group; and R5 is chosen from the group comprising a hydrogen atom, a mono-, di-, tri-, tetra- and penta-mannosyl; and the use of such a composition for manufacturing a medication intended for the prevention or treatment of an illness associated with the over-expression of TNF and/or IL-12 in a subject.

摘要翻译： 本发明涉及包含至少一种式（I）化合物或其药学上可接受的盐之一的药物组合物，其中R 1，R 2和R 3独立地为氢或R 7 -CO-基，其中R 7为烷基， 烯烃或炔基，包括2至24个碳原子的直链，支链或环状基团; R4是通过R6选自氢原子和R7-CO-基团的R6残基在6位上被取代的氢原子或甘露糖基; 并且R 5选自氢原子，单 - ，二 - ，三 - ，四 - 和五 - 甘露糖基; 以及用于制造用于预防或治疗与受试者中TNF和/或IL-12的过度表达相关的疾病的药物的这种组合物的用途。